


# Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. – 9. (Canceled).

10. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

$R^1$  represents  $-C_{2-7}$  alkyl or  $-(CH_2)_m-C_{3-7}$  cycloalkyl;

$R^2$  represents  $-X-C_{3-8}$  cycloalkyl,  $-X$ -aryl,  $-X$ -heteroaryl,  $-X$ -heterocyclyl,  $-X-C_{3-8}$  cycloalkyl- $Y-C_{3-8}$  cycloalkyl,  $-X-C_{3-8}$  cycloalkyl- $Y$ -aryl,  $-X-C_{3-8}$  cycloalkyl- $Y$ -heteroaryl,  $-X-C_{3-8}$  cycloalkyl- $Y$ -heterocyclyl,  $-X$ -aryl- $Y-C_{3-8}$  cycloalkyl,  $-X$ -aryl- $Y$ -heteroaryl,  $-X$ -aryl- $Y$ -heterocyclyl,  $-X$ -heteroaryl- $Y-C_{3-8}$  cycloalkyl,  $-X$ -heteroaryl- $Y$ -aryl,  $-X$ -heteroaryl- $Y$ -heteroaryl,  $-X$ -heteroaryl- $Y$ -heterocyclyl,  $-X$ -heterocyclyl- $Z$ -aryl,  $-X$ -heterocyclyl- $Y-C_{3-8}$  cycloalkyl,  $-X$ -heterocyclyl- $Y$ -heteroaryl or  $-X$ -heterocyclyl- $W$ -heterocyclyl, such that  $R^2$  is linked to O via a carbon atom;

$W$  represents a bond,  $C_{1-6}$  alkyl, CO,  $COC_{2-6}$  alkenyl, O or  $SO_2$ ;

$X$  represents a bond or methyl  $C_{1-6}$ alkyl;

$Y$  represents a bond,  $C_{1-6}$  alkyl, CO,  $COC_{2-6}$  alkenyl, O or  $SO_2$ ;

$Z$  represents a bond, CO,  $COC_{2-6}$  alkenyl, O or  $SO_2$ ;

$R^3$  represents halogen,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, cyano, amino or trifluoromethyl;

$m$  represents an integer from 1-3;

$n$  is 0, 1 or 2;

wherein said alkyl groups of R<sup>1</sup> may be optionally substituted by one or more substituents which may be the same or different and which are selected from the group consisting of halogen, cyano, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, haloC<sub>1-6</sub> alkyl and haloC<sub>1-6</sub> alkoxy;

wherein said cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R<sup>2</sup> may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, =O, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C<sub>1-6</sub> alkyl, pentafluoroethyl, C<sub>1-6</sub> alkoxy, arylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkoxycarbonyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC<sub>1-6</sub> alkyl, aryloxy, C<sub>1-6</sub> alkylsulfonamido, C<sub>1-6</sub> alkylamino, C<sub>1-6</sub> alkylamido, -R<sup>4</sup>, -CO<sub>2</sub>R<sup>4</sup>, -COR<sup>4</sup>, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC<sub>1-6</sub> alkyl, arylcarboxamidoC<sub>1-6</sub> alkyl, aroyl, aroylC<sub>1-6</sub> alkyl, arylC<sub>1-6</sub> alkanoyl, or a group -NR<sup>5</sup>R<sup>6</sup>, -C<sub>1-6</sub> alkyl-NR<sup>5</sup>R<sup>6</sup>, -C<sub>3-8</sub> cycloalkyl-NR<sup>5</sup>R<sup>6</sup>, -CONR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>COR<sup>6</sup>, -NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>, -OCONR<sup>5</sup>R<sup>6</sup>, -NR<sup>5</sup>CO<sub>2</sub>R<sup>6</sup>, -NR<sup>4</sup>CONR<sup>5</sup>R<sup>6</sup> and -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, wherein R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen, C<sub>1-6</sub> alkyl, -C<sub>3-8</sub> cycloalkyl, -C<sub>1-6</sub> alkyl-C<sub>3-8</sub> cycloalkyl, aryl, heterocyclyl or heteroaryl or wherein-NR<sup>5</sup>R<sup>6</sup> may represent a nitrogen containing heterocyclyl group, wherein said R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> groups may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, cyano, amino, =O and trifluoromethyl;

~~or solvates thereof~~ with the proviso that a compound of formula (I) is not 3-cyclopropylmethyl-7-(1-isopropyl-piperidin-4-yloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine.

11. (Currently Amended) A compound as defined in claim 10 which is:

1-(5-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy}-2-pyrazinyl)-2-pyrrolidinone;

3-(1-methylethyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
 3-(2-methylpropyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
 3-Ethyl-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
 3-(cyclopropylmethyl)-7-[(4-piperidinylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
 4-{[4-({[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}methyl)-1-piperidinyl]carbonyl}benzonitrile;  
 3-(cyclopropylmethyl)-7-[(1-[(4-fluorophenyl)carbonyl]-4-piperidinyl)methyl]oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
 7-({[1-(cyclopropylcarbonyl)-4-piperidinyl]methyl}oxy)-3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
 3-(cyclopropylmethyl)-7-({[1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-4-piperidinyl]methyl}oxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;  
 1-(6-{[3-(1-methylethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;  
 1-(6-{[3-(2-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;  
 1-(6-{[3-(2,2-dimethylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;  
 1-(6-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;  
 1-{6-[(3-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone;  
 1-(6-{[3-(1-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;  
 1-(6-{[3-(cyclobutylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;  
 3-(cyclopropylmethyl)-7-{{[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy}-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

1-(4-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}phenyl)-3-methyl-2-imidazolidinone;

3-(cyclopropylmethyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

7-[(3-cyclohexylpropyl)oxy]-3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(cyclopropylmethyl)-7-(phenyloxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

Ethyl 4-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}benzoate;

6-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-*N*-methyl-3-pyridinecarboxamide;

5-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-*N*-methyl-2-pyrazinecarboxamide;

1,1-dimethylethyl 4-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-1-piperidinecarboxylate;

3-(cyclopropylmethyl)-7-(4-piperidinyloxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

4-[(4-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-1-piperidinyl)carbonyl]benzonitrile;

1-(5-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1-(5-{[3-(2-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1-(5-{[3-(1-methylethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1,1-dimethylethyl 4-([3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy)methyl)-1-piperidinecarboxylate;

3-(cyclopropylmethyl)-7-[(4-iodophenyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;


or a pharmaceutically acceptable salt or solvate thereof.

12. (Previously Presented) A pharmaceutical composition which comprises the compound of claim 10 or a pharmaceutically acceptable salt ~~or solvate~~ thereof and a pharmaceutically acceptable carrier or excipient.

13. (Currently Amended) A method of treatment of neurological diseases which comprises administering to a ~~host~~ human in need thereof an effective amount of a compound claim 10 or a pharmaceutically acceptable salt ~~or solvate~~ thereof, wherein said neurological disease is selected Alzheimer's disease, age-related memory dysfunction, and mild cognitive impairment.

14. (Currently Amended) A process for the preparation of a compound of Claim 10 ~~formula (I)~~ or a pharmaceutically acceptable salt ~~or solvate~~ thereof, which process comprises:


(a) reacting a compound of formula (II)



(II)

wherein  $R^1$ ,  $R^3$  and  $n$  are as defined in claim 10, with a compound of formula  $R^{2'}-L^1$ , wherein  $R^{2'}$  is as defined in claim 10 for  $R^2$  or a group convertible thereto and  $L^1$  represents a suitable leaving group ~~such as a halogen atom or an optionally activated hydroxyl group~~;

(b) reacting a compound of formula (III)



(III)

wherein  $R^2$ ,  $R^3$  and  $n$  are as defined in claim 10, with a compound of formula  $R^{1'}-L^2$ , wherein  $R^{1'}$  is as defined in claim 10 for  $R^1$  or a group convertible thereto and  $L^2$  represents a suitable leaving group ~~such as a halogen atom~~; or

(c) reacting a compound of formula (III) as defined above, with a ketone of formula  $R^{1''}=O$ , wherein  $R^{1''}$  is  $=C_{2-7}$  alkyl or  $=(CH_2)_m-C_{3-7}$  cycloalkyl or a group convertible thereto; or

(d) deprotecting a compound of formula (I) which is protected; or

(e) interconversion from one compound of formula (I) to another.